CARSON CITY, NV, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pharmagreen Biotech, Inc. (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has completed its migration to Health Canada's Cannabis Tracking and Licensing System, or CTLS. The CTLS is the Health Canada’s worldwide web portal that enables the submission of new license applications, request for amendments, and license renewals in addition to submission of monthly tracking reports.
All submitted applications to Health Canada for the Access to Cannabis for Medical Purposes Regulations (ACMPR) prior to October 17, 2018 are required to migrate to the CTLS digital system on or before January 31, 2019. This new licensing system is designed to service the new recreational market while still including the provisions for supplying the medical cannabis license holders as was under the former application process in place prior to October 17, 2018.
The oversight of the cannabis supply chain is a shared responsibility across many Federal, Provincial and Territorial governmental departments, industry and other stakeholders. One of Health Canada's responsibilities is to track the flow of cannabis as a means of preventing the illegal inversion and diversion of cannabis into and out of the regulated system. Under this tracking system, a holder of a license for cultivation, a license for processing, or a license for sale for medical and/or recreational purposes is required to submit monthly reports to Health Canada.
Commenting on Pharmagreen’s progress, Peter Wojcik, President and CEO, stated, “Our business plan is being rolled out as planned and this is an important and pivotal step in continuing to move the company’s Health Canada cannabis licensing process ahead.”
About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.
WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreens’ mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company progress on the construction of a 63,000 square foot “Cannabis Biotech Complex” please visit www.pharmagreen.ca
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
Tel: (702) 803 9404